ASCO 2020 - Grohé Poster

Nintedanib plus docetaxel in lung adenocarcinoma patients following treatment with immune checkpoint inhibitors: updated efficacy and safety results of the ongoing non-interventional study VARGADO (NCT02392455)

Grohé C, Blau W, Gleiber W, Haas S, Krüger S, Müller-Huesmann H, Schulze M, Atz J, Kaiser R


ASCO 2020

Audio Recording

Listen to Professor Christian Grohé present the latest results from the VARGADO study.

Related articles

Learn more about the efficacy and safety of nintedanib* plus docetaxel in this setting below.


Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma (includes video abstract)

Grohé C, et al. Future Oncol 2019;15(23):2699–706.

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib named patient use program

Corral J, et al. Clin Transl Oncol 2019;21(9):1270–9.

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.


© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: May 2020